Semaglutide-Glycine-Cyanocobalamin Injectable Vials Recalled Due to Lack of Sterility Assurance
Payless Compounders, LLC is recalling Semaglutide-Glycine-Cyanocobalamin Injectable vials because there is no assurance that the product is sterile.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of sterility assurance for an injectable medication, which poses a significant risk of harm.
Plain-English summary
Payless Compounders, LLC is recalling Semaglutide-Glycine-Cyanocobalamin Injectable (2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials) due to a lack of assurance of sterility.
The affected product includes Lot Number [email protected]. The distribution is limited to Oregon.
Consumers and healthcare providers should check their stock for the affected lot number and contact the manufacturer or their healthcare provider for further guidance.
The recalled product
- Product
- Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
- Manufacturer
- PAYLESS COMPOUNDERS, LLC
- Category
- Drug — Injectable
- Hazard
- Affected units
- 91
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot Number [email protected]
Distribution
Distributed in 1 state:
Related recalls
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15